TREATMENT OF CHRONIC HEPATITIS C IN CHILDREN WITH PEGYLATED INTERFERON α2a AND RIBAVIRIN - A MULTI-CENTER STUDY

被引：0

作者：

Sluzewski, Wojciech ^{[2
]}

Kowala-Piaskowska, Arleta ^{[1
]}

Wysocki, Jacek ^{[3
]}

Figlerowicz, Magdalena ^{[2
]}

Gorczyca, Anna ^{[4
]}

Halota, Waldemar ^{[5
]}

Jozwiak, Hanna ^{[6
]}

Mizerski, Jacek ^{[4
]}

Mozer-Lisewska, Iwona ^{[1
]}

Pawlowska, Malgorzata ^{[5
]}

Rokitka, Maria ^{[4
]}

Strawinska, Elzbieta ^{[7
]}

Szamotulska, Katarzyna ^{[8
]}

机构：

[1] Univ Med Sci, Fac Med, Dept Infectuous Deseases, PL-61285 Poznan, Poland

[2] Univ Med Sci, Fac Med, Dept Infectuous Dis & Child Neurol, PL-61285 Poznan, Poland

[3] Univ Med Sci, Dept Prevent Med, PL-61285 Poznan, Poland

[4] John Paul 2 Hosp, Dept Childrens Infect Deseases, Krakow, Poland

[5] Nicolaus Copernicus Univ, Coll Med, Dept Infect Deseases & Hepatol, Bydgoszcz, Poland

[6] Specialist Reg Ctr Mother & Child Hlth Care, Poznan, Poland

[7] Voivodship Hosp Infect Deseases & Observat, Torun, Poland

[8] Natl Res Inst Mother & Child, Warsaw, Poland

来源：

ACTA POLONIAE PHARMACEUTICA | 2012年 / 69卷 / 02期

关键词：

chronic hepatitis C; combined therapy in children with CHC; pegylated interferon; sustained virological response; EARLY VIROLOGICAL RESPONSE; PLUS RIBAVIRIN; THERAPY; COMBINATION; ADOLESCENTS; EFFICACY; SAFETY;

D O I：

暂无

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Pegylated interferon a and ribavirin in treatment of chronic hepatitis C in children is used rarely. The aim of the study was to find prognostic factors for sustained virologica. response and to analyze the safety of pegylated interferon alpha 2a and ribavirin in children with chronic hepatitis C. The study covered a group of 44 children, mean age 14 years, with diagnosed chronic hepatitis C. Clinical, biochemical and virological parameters, as well as side effects were evaluated. Combined treatment allowed to obtain sustained virological response in a total of 77.5% of the treated children. Lower viral load and lower fibrosis grade contributed to sustained virological response. The response was not gender-related. The best response is obtained in children whose treatment was started after they attained the age of 10 years. Therapy with pegylated interferon alpha 2a and ribavirin is well tolerated by pediatric patients.

引用

页码：319 / 326

页数：8

共 26 条

[1] Therapy of hepatitis C: Meta-analysis of interferon alfa-2b trials
Carithers, RL
Emerson, SS
[J]. HEPATOLOGY, 1997, 26 (03) : S83 - S88
[2] Cianciara J., 1997, HEPATOLOGIA POLSKA, V4, P147
[3] The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen
Crotty, S
Maag, D
Arnold, JJ
Zhong, WD
Lau, JYN
Hong, Z
Andino, R
Cameron, CE
[J]. NATURE MEDICINE, 2000, 6 (12) : 1375 - 1379
[4] RNA virus error catastrophe: Direct molecular test by using ribavirin
Crotty, S
Cameron, CE
Andino, R
[J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (12) : 6895 - 6900
[5] Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C
Davis, GL
Wong, JB
McHutchison, JG
Manns, MP
Harvey, J
Albrecht, J
[J]. HEPATOLOGY, 2003, 38 (03) : 645 - 652
[6] Predicting the therapeutic response in patients with chronic hepatitis C: the role of viral kinetic studies
Ferenci, P
[J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2004, 53 (01) : 15 - 18
[7] Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
Fried, MW
Shiffman, ML
Reddy, KR
Smith, C
Marinos, G
Goncales, FL
Haussinger, D
Diago, M
Carosi, G
Dhumeaux, D
Craxi, A
Lin, A
Hoffman, J
Yu, J
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (13) : 975 - 982
[8] Chronic hepatitis C in children:: A clinical and immunohistochemical comparative study with adult patients
García-Monzón, C
Jara, P
Fernández-Bermejo, M
Hierro, L
Frauca, E
Camarena, C
Díaz, C
De La Vega, A
Larrauri, J
García-Iglesias, C
Borque, MJ
Sanz, P
García-Buey, L
Moreno-Monteagudo, JA
Moreno-Otero, R
[J]. HEPATOLOGY, 1998, 28 (06) : 1696 - 1701
[9] Interferon alfa-2b in combination with ribavirin for the treatment of chronic hepatitis C in children:: Efficacy, safety, and pharmacokinetics
González-Peralta, RP
Kelly, DA
Haber, B
Molleston, J
Murray, KF
Jonas, MM
Shelton, M
Mieli-Vergani, G
Lurie, Y
Martin, S
Lang, T
Baczkowski, A
Geffner, M
Gupta, S
Laughlin, M
[J]. HEPATOLOGY, 2005, 42 (05) : 1010 - 1018
[10] Chronic hepatitis C virus management: 2000-2005 update
Hughes, CA
Shafran, SD
[J]. ANNALS OF PHARMACOTHERAPY, 2006, 40 (01) : 74 - 82

← 1 2 3 →